Literature DB >> 18800150

Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.

Katharina Steinmann1, Lan Kluwe, Reinhard E Friedrich, Victor-Felix Mautner, David N Cooper, Hildegard Kehrer-Sawatzki.   

Abstract

Plexiform neurofibromas constitute a serious burden for patients with neurofibromatosis type 1 (NF1), a common autosomal dominant disorder characterized by pigmentary changes and tumorous skin lesions (neurofibromas). Despite the prominence of these benign tumors in NF1 patients, the mechanisms underlying the tumor-associated loss of heterozygosity (LOH) in plexiform neurofibromas have not been extensively studied. We performed LOH analysis on 43 plexiform neurofibromas from 31 NF1 patients, the largest study of its kind to date. A total of 13 (30%) plexiform neurofibromas exhibited LOH involving 17q markers. In three tumors, LOH was found to be confined to the NF1 gene region. However, in none of the tumors was a somatic NF1 microdeletion, mediated by non-allelic homologous recombination between either NF1-REPs or SUZ12 genes, detected. Thus, NF1 microdeletions do not appear to be frequent somatic events in plexiform neurofibromas. Determination of NF1 gene copy number by multiplex ligation-dependent probe amplification indicated that although tumors with smaller regions of LOH were characterized by 17q deletions, no NF1 gene copy number changes were detected in six plexiform neurofibromas with more extensive LOH. To our knowledge, mitotic recombination has not previously been reported to be a frequent cause of LOH in plexiform neurofibromas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18800150     DOI: 10.1038/jid.2008.274

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  Mitotic recombination of chromosome arm 17q as a cause of loss of heterozygosity of NF1 in neurofibromatosis type 1-associated glomus tumors.

Authors:  Douglas R Stewart; Alexander Pemov; Peter Van Loo; Eline Beert; Hilde Brems; Raf Sciot; Kathleen Claes; Evgenia Pak; Amalia Dutra; Chyi-Chia Richard Lee; Eric Legius
Journal:  Genes Chromosomes Cancer       Date:  2012-01-17       Impact factor: 5.006

Review 2.  [How frequently does genetic mosaicism occur in the skin?].

Authors:  R Happle
Journal:  Hautarzt       Date:  2014-06       Impact factor: 0.751

3.  Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: Importance of copy neutral LOH.

Authors:  Carles Garcia-Linares; Juana Fernández-Rodríguez; Ernest Terribas; Jaume Mercadé; Eva Pros; Llúcia Benito; Yolanda Benavente; Gabriel Capellà; Anna Ravella; Ignacio Blanco; Hildegard Kehrer-Sawatzki; Conxi Lázaro; Eduard Serra
Journal:  Hum Mutat       Date:  2011-01       Impact factor: 4.878

Review 4.  Neurofibromin and suppression of tumorigenesis: beyond the GAP.

Authors:  Juan Mo; Stefanie L Moye; Renee M McKay; Lu Q Le
Journal:  Oncogene       Date:  2022-01-23       Impact factor: 8.756

5.  Mice with missense and nonsense NF1 mutations display divergent phenotypes compared with human neurofibromatosis type I.

Authors:  Kairong Li; Ashley N Turner; Min Chen; Stephanie N Brosius; Trenton R Schoeb; Ludwine M Messiaen; David M Bedwell; Kurt R Zinn; Corina Anastasaki; David H Gutmann; Bruce R Korf; Robert A Kesterson
Journal:  Dis Model Mech       Date:  2016-06-02       Impact factor: 5.758

6.  The investigation for potential modifier genes in patients with neurofibromatosis type 1 based on next-generation sequencing.

Authors:  Fan Yang; Song Xu; Renwang Liu; Tao Shi; Xiongfei Li; Xuebing Li; Gang Chen; Hongyu Liu; Qinghua Zhou; Jun Chen
Journal:  Onco Targets Ther       Date:  2018-02-21       Impact factor: 4.147

7.  Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.

Authors:  Meritxell Carrió; Helena Mazuelas; Yvonne Richaud-Patin; Bernat Gel; Ernest Terribas; Imma Rosas; Senda Jimenez-Delgado; Josep Biayna; Leen Vendredy; Ignacio Blanco; Elisabeth Castellanos; Conxi Lázaro; Ángel Raya; Eduard Serra
Journal:  Stem Cell Reports       Date:  2019-01-31       Impact factor: 7.765

8.  Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1.

Authors:  Sara H Isakson; Anthony E Rizzardi; Alexander W Coutts; Daniel F Carlson; Mark N Kirstein; James Fisher; Jeremie Vitte; Kyle B Williams; G Elizabeth Pluhar; Sonika Dahiya; Brigitte C Widemann; Eva Dombi; Tilat Rizvi; Nancy Ratner; Ludwine Messiaen; Anat O Stemmer-Rachamimov; Scott C Fahrenkrug; David H Gutmann; Marco Giovannini; Christopher L Moertel; David A Largaespada; Adrienne L Watson
Journal:  Commun Biol       Date:  2018-10-02

Review 9.  A six-attribute classification of genetic mosaicism.

Authors:  Luis A Pérez-Jurado; Víctor L Ruiz Pérez; Antonio Torrelo; Nancy B Spinner; Rudolf Happle; Leslie G Biesecker; Pablo Lapunzina; Víctor Martínez-Glez; Jair Tenorio; Julián Nevado; Gema Gordo; Lara Rodríguez-Laguna; Marta Feito; Raúl de Lucas
Journal:  Genet Med       Date:  2020-07-14       Impact factor: 8.864

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.